^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FOLR1 ( Folate receptor alpha )

    i
    Apply
    First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (IMGN151-1001) (NCT05527184)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/11/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    FOLR1
    |
    opugotamig olatansine (IMGN-151)
    FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT06609928)
    Phase 1
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    03/12/2025
    Primary completion :
    10/01/2027
    Completion :
    10/01/2042
    FOLR1
    |
    cyclophosphamide • fludarabine IV
    Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (SL03-OHD-105) (NCT05483933)
    Phase 1
    Shattuck Labs, Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    08/18/2022
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    FOLR1
    |
    FOLR1 expression
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer (NCT05456685)
    Phase 2
    AbbVie
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    09/28/2022
    Primary completion :
    05/12/2026
    Completion :
    05/12/2026
    FOLR1 • BRCA
    |
    FOLR1 expression
    |
    carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (CA116-001) (NCT05613088)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    11/21/2024
    Initiation :
    02/01/2023
    Primary completion :
    06/05/2024
    Completion :
    10/11/2026
    FOLR1
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)
    A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) (NCT03835819)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    11/08/2024
    Initiation :
    01/02/2020
    Primary completion :
    06/04/2024
    Completion :
    05/01/2027
    FOLR1 • MLH1 • MSH6 • MSH2
    |
    MSH6 expression
    |
    Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)
    A Study of CBP-1018 in Patients With Advanced Solid Tumors (NCT04928612)
    Phase 1
    Coherent Biopharma (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    08/28/2024
    Initiation :
    11/04/2021
    Primary completion :
    10/01/2024
    Completion :
    12/01/2024
    FOLR1
    |
    CBP-1018
    Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer (NCT03832361)
    Phase 2
    Alessandro Santin
    Recruiting
    Last update posted :
    08/20/2024
    Initiation :
    07/15/2020
    Primary completion :
    10/01/2025
    Completion :
    10/01/2028
    FOLR1
    |
    Elahere (mirvetuximab soravtansine-gynx)
    Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (KEYNOTE PN409) (NCT02606305)
    Phase 1/2
    ImmunoGen, Inc.
    Completed
    Last update posted :
    06/14/2024
    Initiation :
    03/02/2016
    Primary completion :
    03/12/2021
    Completion :
    03/12/2021
    FOLR1
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx)
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) (NCT05445778)
    Phase 3
    ImmunoGen, Inc.
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/27/2022
    Primary completion :
    03/01/2027
    Completion :
    04/01/2029
    FOLR1 • BRCA • MUC16
    |
    FOLR1 expression • MUC16 elevation
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    PRO1184 for Advanced Solid Tumors (PRO1184-001) (NCT05579366)
    Phase 1/2
    ProfoundBio US Co.
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    12/07/2022
    Primary completion :
    10/01/2025
    Completion :
    04/01/2026
    HER-2 • FOLR1
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • rinatabart sesutecan (PRO1184)
    Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) (NCT05041257)
    Phase 2
    ImmunoGen, Inc.
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    08/31/2021
    Primary completion :
    01/17/2024
    Completion :
    12/13/2024
    FOLR1 • BRCA
    |
    FOLR1 expression • BRCA mutation
    |
    Elahere (mirvetuximab soravtansine-gynx)
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (NCT05870748)
    Phase 2/3
    Sutro Biopharma, Inc.
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    07/12/2023
    Primary completion :
    09/01/2025
    Completion :
    02/01/2026
    FOLR1
    |
    FOLR1 expression • FOLR1 positive
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
    A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (ELU-FRα-1) (NCT05001282)
    Phase 1/2
    Elucida Oncology
    Recruiting
    Last update posted :
    03/28/2024
    Initiation :
    09/13/2021
    Primary completion :
    06/15/2024
    Completion :
    06/15/2025
    FOLR1
    |
    FOLR1 expression
    |
    ELU001
    Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (MIROVA) (NCT04274426)
    Phase 2
    AGO Research GmbH
    Recruiting
    Last update posted :
    01/15/2024
    Initiation :
    10/13/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BRCA1 • BRCA2 • FOLR1 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal
    Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection (NCT05378737)
    Phase 1
    Bio-Thera Solutions
    Recruiting
    Last update posted :
    12/22/2023
    Initiation :
    07/06/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    FOLR1
    |
    FOLR1 expression
    A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors (NCT05830097)
    Phase 1/2
    Coherent Biopharma (Hefei) Co., Ltd.
    Recruiting
    Last update posted :
    12/12/2023
    Initiation :
    03/14/2023
    Primary completion :
    06/30/2025
    Completion :
    09/30/2025
    FOLR1 • TRPV6
    |
    CBP-1019
    A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) (NCT04209855)
    Phase 3
    ImmunoGen, Inc.
    Active, not recruiting
    Last update posted :
    03/06/2023
    Initiation :
    12/31/2019
    Primary completion :
    09/01/2023
    Completion :
    04/01/2024
    FOLR1
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal
    A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer (NCT05622890)
    Phase 3
    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    11/21/2022
    Initiation :
    08/18/2022
    Primary completion :
    04/30/2023
    Completion :
    12/31/2023
    FOLR1 • MUC16
    |
    Elahere (mirvetuximab soravtansine-gynx)
    Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer (NCT02317705)
    Phase 2
    On Target Laboratories, LLC
    Completed
    Last update posted :
    06/21/2022
    Initiation :
    12/01/2014
    Primary completion :
    11/01/2015
    Completion :
    11/01/2015
    FOLR1
    |
    FOLR1 positive
    Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer (NCT02593227)
    Phase 2
    Marker Therapeutics, Inc.
    Completed
    Last update posted :
    07/19/2021
    Initiation :
    04/01/2016
    Primary completion :
    07/15/2021
    Completion :
    07/15/2021
    HER-2 • FOLR1
    |
    FOLR1 expression
    |
    cyclophosphamide • TPIV200 • cyclophosphamide intravenous
    First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors (IMGN-0401) (NCT01609556)
    Phase 1
    ImmunoGen, Inc.
    Completed
    Last update posted :
    02/17/2021
    Initiation :
    06/28/2012
    Primary completion :
    03/19/2018
    Completion :
    03/19/2018
    FOLR1
    |
    Elahere (mirvetuximab soravtansine-gynx)
    A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I) (NCT02631876)
    Phase 3
    ImmunoGen, Inc.
    Completed
    Last update posted :
    10/14/2020
    Initiation :
    03/02/2016
    Primary completion :
    01/01/2019
    Completion :
    01/01/2020
    FOLR1
    |
    FOLR1 positive
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal
    A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung (MORAb-003-009) (NCT01218516)
    Phase 2
    Morphotek
    Completed
    Last update posted :
    08/20/2020
    Initiation :
    06/27/2011
    Primary completion :
    12/15/2012
    Completion :
    11/01/2013
    FOLR1
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • farletuzumab (MORAB-003)
    A Study of MORAb-003 in Patients With Solid Tumor (MORAB-003-J081-102) (NCT01049061)
    Phase 1
    Eisai Co., Ltd.
    Completed
    Last update posted :
    06/11/2020
    Initiation :
    01/01/2010
    Primary completion :
    01/01/2013
    Completion :
    02/01/2013
    FOLR1
    |
    FOLR1 expression
    |
    farletuzumab (MORAB-003)
    Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer (NCT03836157)
    Phase 2
    University of Oklahoma
    Withdrawn
    Last update posted :
    06/27/2019
    Initiation :
    05/31/2019
    Primary completion :
    11/30/2021
    Completion :
    05/01/2022
    FOLR1
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer (PointBreak) (NCT00762034)
    Phase 3
    Eli Lilly and Company
    Completed
    Last update posted :
    12/21/2015
    Initiation :
    12/01/2008
    Primary completion :
    04/01/2012
    Completion :
    12/01/2014
    EGFR • FOLR1 • TTF1 • TYMS • NKX2-1
    |
    EGFR mutation • TTF1 negative • TYMS expression
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • pemetrexed
    Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer (NCT00019136)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    04/29/2015
    Initiation :
    02/01/1997
    FOLR1
    |
    cisplatin • Proleukin (aldesleukin)